Key Executives
| Name | Title | Pay | Exercised | Year Born |
|---|---|---|---|---|
| Mr. Joel Bradley Latham | President, CEO & Executive Director | 704.07k | -- | 1989 |
| Mr. Joseph Swan | CFO, Treasurer & Secretary | 134.81k | -- | 1991 |
| Mr. Lekhram Changoer M.Sc. | CTO & Member of Advisory Board | 137.65k | -- | 1967 |
| Dr. Mark Bleackley Ph.D. | Chief Scientific Officer, Head of Programs & Member of the Advisory Board | -- | -- | -- |
| Mr. John Michailidis B.Sc., EMBA, M.A.I.C.D. | Chief Executive Officer of IncannexTM | -- | -- | -- |
| Natalie May | Head of Clinical Operations | -- | -- | -- |
| Dr. Luigi M. Barbato M.D. | Chief Medical Officer | -- | -- | -- |
Incannex Healthcare Inc.
- Sector:
- Healthcare
- Industry: Drug Manufacturers - Specialty & Generic
- Full Time Employees:
- 9
Description
Incannex Healthcare Inc., a clinical-stage biopharmaceutical company, engages in the research, development, manufacture, sale, and distribution of psychedelic medicines and therapies for patients with chronic diseases in Australia. The company develops IHL-42X, an oral fixed dose combination of dronabinol and acetazolamide that has completed Phase 2/3 clinical trial for the treatment of obstructive sleep apnea; and PSX-001, an oral synthetic psilocybin treatment in Phase 2b clinical development for patients with generalized anxiety disorder. It is also developing IHL-675A, an oral fixed dose combination drug containing synthetic cannabidiol and hydroxychloroquine sulphate in Phase 2 clinical trial to treat rheumatoid arthritis, as well as lung inflammation, acute respiratory disease, chronic obstructive pulmonary disease, asthma, bronchitis, inflammatory bowel disease, colitis, and Crohn's disease. Incannex Healthcare Inc. is headquartered in Sydney, Australia.
Corporate Governance
Upcoming Events
February 14, 2025 at 12:30 PM UTC
Incannex Healthcare Inc. Earnings Date